Chloroprocaine Hydrochloride Injection in single-dose containers without preservative and without EDTA, is indicated for the production oflocal anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks.Chloroprocaine Hydrochloride Injection is not to be used for subarachnoid administration.

---

Absence of sensation --

Chloroprocaine Hydrochloride Injection is contraindicated in patients hypersensitive (allergic) to drugs of the PABA ester group.Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: existing neurological disease, spinal deformities, septicemia and severe hypertension.

---

Absence of sensation --

nervous system disorder -- Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle.

Septicemia -- systemic disease associated with presence and persistance of pathogenic microorganisms or their toxins in the blood.

Hypertensive disease -- Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.

LOCAL ANESTHETICS SHOULD ONLY BE EMPLOYED BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES WHICH MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED, AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY RESUSCITATIVE EQUIPMENT, AND THE PERSONNEL RESOURCES NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (See also ADVERSE REACTIONS and PRECAUTIONS.) DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH.Chloroprocaine Hydrochloride Injection, contains no preservative; discard unused injection remaining in vial after initial use.Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur.To avoid intravascular injection, aspiration should be performed before the anesthetic solution is injected.

The needle must be repositioned until no blood return can be elicited.

However, the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.Mixtures of local anesthetics are sometimes employed to compensate for the slower onset of one drug and the shorter duration of action of the second drug.

Experiments in primates suggest that toxicity is probably additive when mixtures of local anesthetics are employed, but some experiments in rodents suggest synergism.

Caution regarding toxic equivalence should be exercised when mixtures of local anesthetics are employed.Chloroprocaine Hydrochloride Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.

The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.

Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

The following US Branded drugs contain Chloroprocaine Hydrochloride

---

NESACAINE -- APP PHARMACEUTICALS LLC

NESACAINE-MPF -- APP PHARMACEUTICALS LLC